" class="no-js "lang="en-US"> Enoch Kariuki - Medtech Alert
Tuesday, August 05, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Enoch Kariuki

Enoch Kariuki

About Enoch Kariuki

Accomplished biotech executive with broad experience in life sciences finance, strategy and operations. CEO of Lengo Therapeutics, a precision oncology biotech. Previously served as the Chief Financial Officer of VelosBio (acquired by Merck for $2.75 billion in 2020) where I led all finance-related and investor relations functions.

Prior to VelosBio, I served as Senior Vice President, Corporate Development at Synthorx, where I led the company’s $151 million IPO, managed relationships with bankers, sell-side equity analysts and investors, and headed the business development process that concluded with the successful sale of Synthorx to Sanofi for $2.5 billion in 2019.

Previously worked in investment banking and private equity focused on life sciences companies. Trained as a pharmacist and completed a post doctoral fellowship in R&D strategy at BMS.

Related Story

Diseases

 Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics | Pharmtech Focus

Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics

November 29 2021

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the company has entered into a definitive agreement […]